ImageneBio Inc. (IMA)
IMA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/0001193125-26-099434-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IMA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001835579 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $800K |
| Net income | -$45.3M |
| Operating income | -$48.5M |
| Net margin | -5668.6% |
| Operating margin | -6056.4% |
| Revenue growth | -77.1% |
| Cash | $94.5M |
| Total assets | $153.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 49.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $84.9M cash; operating cash flow -$10.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 12,456,281 (2026-10-31); 11,181,672 a year earlier; 48,258,111 three years earlier. 3y figure adjusted for split (1-for-12 overall). | Cover page 2026-10-31 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2025-07-28 | Source 2025-07-28 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-08-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Diego, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-08-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $96K, sold $17K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$15.6M | -$9.5M | $84.9M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$10.2M | -$9.1M | $94.7M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$10.6M | -$14.8M | $76.0M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | $0 | -$6.9M | -$7.2M | $94.5M | $0 | $800K | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | $0 | -$24.8M | -$21.5M | $103.2M | $0 | $800K | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $0 | -$7.6M | -$11.9M | $58.3M | No debt tags | $4.3M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $800K | -$6.1M | -$7.2M | $36.8M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $0 | -$4.8M | -$3.5M | $12.1M | $8.6M | $3.5M | 10-K 2026-03-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-05 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 339 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.5% |
| 1 month | -18.2% |
| 3 months | -40.9% |
| Year to date | -49.7% |
| 1 year | -58.3% |
| From 52-week high | -57.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TIL | Instil Bio Inc. | $5.75 | -5.43% | $39.0M |
| CRBU | Caribou Biosciences Inc. | $0.3528 | -2.51% | $38.1M |
| EXOZ | eXoZymes Inc. | $3.99 | +4.18% | $37.1M |
| ELUT | Elutia Inc. | $0.8229 | +0.35% | $36.5M |
| KLRS | Kalaris Therapeutics Inc. | $1.46 | -7.30% | $34.8M |
| INKT | MiNK Therapeutics Inc. | $9.35 | +0.11% | $48.0M |
| ELOX | Eloxx Pharmaceuticals Inc. | $12.75 | -3.04% | $51.5M |
| GRML | Greenland Mines Ltd. | $3.50 | -3.05% | $51.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier